VIPoma historical perspective: Difference between revisions
Jump to navigation
Jump to search
Homa Najafi (talk | contribs) No edit summary |
Homa Najafi (talk | contribs) No edit summary |
||
| Line 14: | Line 14: | ||
[[Category:Medicine]] | [[Category:Medicine]] | ||
[[Category:Oncology]] | [[Category:Oncology]] | ||
Revision as of 15:32, 16 September 2019
|
VIPoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
VIPoma historical perspective On the Web |
|
American Roentgen Ray Society Images of VIPoma historical perspective |
|
Risk calculators and risk factors for VIPoma historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Madhu Sigdel M.B.B.S.[2]Parminder Dhingra, M.D. [3] Homa Najafi, M.D.[4]
Overview
VIPoma which is also known as Verner-Morrison syndrome was first described in 1958 by Verner and Morrison.
Historical Perspective
- In 1870, Rudolf Heidenhain was the first to discover and describe the neuroendocrine tumors of the gastrointestinal tract and pancreas.
- In 1958, American physicians, John U. Verner and Ashton B. Morrison discovered VIPoma for the first time in a patient presenting with profuse diarrhea and hypokalemia.
- John U. Verner and Ashton B also described the pathogenesis of VIPoma (due to malignancy of non-insulin producing pancreatic islets) in detail.
- VIPoma is also known as Verner-Morrison syndrome.[1]
References
- ↑ Belei OA, Heredea ER, Boeriu E, Marcovici TM, Cerbu S, Mărginean O; et al. (2017). "Verner-Morrison syndrome. Literature review". Rom J Morphol Embryol. 58 (2): 371–376. PMID 28730220.